ERBB2 and glioblastoma: In a recent Phase 1 clinical trial of HER2-specific CAR-T cells on pediatric and young adult glioblastoma patients, Vitanza et al. studied locoregional diffusion to the tumor cavity or ventricular system and showed local activation of CNS immune response without dose-limiting toxicity [127,130].